ReviewJournal of clinical medicine2021
Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Modulation of the skin and gut microbiome by psoriasis treatment: a comprehensive systematic review.Archives of dermatological research · 2024Pooled it
- Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials.Frontiers in immunology · 2022Pooled it
- Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety.Biomolecules & biomedicine · 2026Article
- Effectiveness of Biological Therapy in Psoriasis: Real-World Evaluation of SII and SIRI as Biomarkers of Systemic Inflammation.Dermatology practical & conceptual · 2026Article
- Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.Journal of clinical medicine · 2026Article
- Comparative analysis of candidate gene expression in Asian atopic dermatitis and psoriasis: identification of shared and distinct molecular features.Frontiers in medicine · 2026Article
- Head and Neck Malignancies in Autoimmune Polyendocrine Syndrome Type 1 (APS-1/APECED): A Scoping Review of Molecular Pathogenesis, Clinical Features, and Outcomes.International journal of molecular sciences · 2025Article
- Unravelling the gut-skin axis: the role of gut microbiota in pathogenesis and management of psoriasis.Inflammopharmacology · 2025Review
- Article
- Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis.Dermatology practical & conceptual · 2024Article
- Psoriasis and Its Relationship With Somatosensory Amplification, Health Anxiety, and Depression.Cureus · 2023Article
- Psoriasis Area and Severity Index (PASI) Objectivisation by Flow Cytometry Analysis of Major Lymphocytes Subsets.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2023Article
- S100 calcium-binding protein A9 promotes skin regeneration through toll-like receptor 4 during tissue expansion.Burns & trauma · 2023Article
- The Intriguing Links between Psoriasis and Bullous Pemphigoid.Journal of clinical medicine · 2022Review
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.Frontiers in medicine · 2022Review
- Biomarkers in Psoriasis: The Future of Personalised Treatment.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory skin disease induced by multifactorial causes and is characterized by bothersome, scaly reddish plaques, especially on frequently chafed body parts, such as extensor sites of the extremities. The latest advances in molecular-targeted therapies using biologics or small-molecule inhibitors help to sufficiently treat even the most severe psoriatic symptoms and the extra cutaneous comorbidities of psoriatic arthritis. The excellent clinical effects of these therapies provide a deeper understanding of the impaired quality of life caused by this disease and the detailed molecular mechanism in which the interleukin (IL)-23/IL-17 axis plays an essential role. To establish standardized therapeutic strategies, biomarkers that define deep remission are indispensable. Several molecules, such as cytokines, chemokines, antimicrobial peptides, and proteinase inhibitors, have been recognized as potent biomarker candidates. In particular, blood protein markers that are repeatedly measurable can be extremely useful in daily clinical practice. Herein, we summarize the molecular mechanism of psoriasis, and we describe the functions and induction mechanisms of these biomarker candidates.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.